Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants,...
Wanbury reported revenue of 6.00 billion INR for fiscal year 2025, up 3.8% from fiscal year 2024, and net income of 305.30 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.62 billion INR, up 21.7% from a year before. Outside India was its largest region in fiscal year 2025, with 70% of revenue. Its market capitalization was 6.87 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.